Wall Street analysts expect that Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) will post $1.46 million in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Tetraphase Pharmaceuticals’ earnings. The highest sales estimate is $1.88 million and the lowest is $1.00 million. Tetraphase Pharmaceuticals posted sales of $850,000.00 during the same quarter last year, which indicates a positive year over year growth rate of 71.8%. The business is expected to report its next quarterly earnings results on Thursday, November 2nd.

On average, analysts expect that Tetraphase Pharmaceuticals will report full year sales of $1.46 million for the current year, with estimates ranging from $4.99 million to $7.11 million. For the next financial year, analysts anticipate that the firm will post sales of $5.29 million per share, with estimates ranging from $3.00 million to $8.16 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Tetraphase Pharmaceuticals.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by $0.07. Tetraphase Pharmaceuticals had a negative net margin of 2,092.20% and a negative return on equity of 79.79%. The business had revenue of $1.59 million during the quarter, compared to the consensus estimate of $1.54 million. During the same quarter in the previous year, the business posted ($0.47) EPS. The company’s revenue for the quarter was up 28.2% on a year-over-year basis.

Several research analysts have recently weighed in on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Tetraphase Pharmaceuticals in a report on Thursday, July 27th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $13.00 price target (up previously from $12.00) on shares of Tetraphase Pharmaceuticals in a report on Wednesday, July 26th. Stifel Nicolaus raised shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price target for the stock from $8.00 to $15.00 in a report on Wednesday, July 26th. HC Wainwright assumed coverage on shares of Tetraphase Pharmaceuticals in a report on Tuesday, July 11th. They issued a “buy” rating and a $15.00 price target on the stock. Finally, Zacks Investment Research raised shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, July 6th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $10.25.

TRADEMARK VIOLATION NOTICE: This piece was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/07/analysts-anticipate-tetraphase-pharmaceuticals-inc-ttph-will-post-quarterly-sales-of-1-46-million.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Trexquant Investment LP purchased a new position in Tetraphase Pharmaceuticals during the first quarter worth approximately $265,000. Parametric Portfolio Associates LLC boosted its position in Tetraphase Pharmaceuticals by 22.5% in the first quarter. Parametric Portfolio Associates LLC now owns 62,423 shares of the biopharmaceutical company’s stock worth $574,000 after buying an additional 11,458 shares in the last quarter. Wade G W & Inc. purchased a new position in Tetraphase Pharmaceuticals during the first quarter worth approximately $138,000. Teza Capital Management LLC boosted its position in Tetraphase Pharmaceuticals by 8.9% in the first quarter. Teza Capital Management LLC now owns 15,650 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 1,281 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Tetraphase Pharmaceuticals by 3.4% in the first quarter. Bank of New York Mellon Corp now owns 187,897 shares of the biopharmaceutical company’s stock worth $1,726,000 after buying an additional 6,114 shares in the last quarter. 35.76% of the stock is currently owned by institutional investors and hedge funds.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) opened at 5.655 on Monday. The stock has a 50 day moving average price of $7.40 and a 200 day moving average price of $6.92. The company’s market cap is $288.70 million. Tetraphase Pharmaceuticals has a 52 week low of $3.11 and a 52 week high of $9.93.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Get a free copy of the Zacks research report on Tetraphase Pharmaceuticals (TTPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.